A MALARIA vaccine made in Colombia by synthesising protein segments from the malaria parasite is proving promising in field trials, but its efficacy is still low.
Vaccine developer Manuel Patarroyo of the National University of Colombia in Bogota reports the vaccine offers adults 38.8 per cent protection against malaria, but the figure rises to 77 per cent for infants, who are the worst sufferers (New Scientist, Vol 137, No 1866). The Colombian vaccine is the first of its kind to demonstrate any level of success. The vaccine is cheap, costing about 25 cents for the three shots recommended for it to be effective.
Chiron, an American biotech company, is interested in large-scale production of the vaccine, but Patarroyo says he is considering transferring rights to his vaccine to WHO.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.